Medication Management

Newer Psychiatric Medications Explained

By Dr. Stacey Forbes, DNP, APRN, PMHNP-BC · Updated October 12, 2026

Psychiatric drug development moved slowly for decades, with most new medications working much like the ones before them. That has started to change. Since 2022 the FDA has approved several medications with genuinely different mechanisms for depression, postpartum depression, schizophrenia and ADHD. This guide explains what is new about each, who it is approved for, and what is still unknown, so you can have an informed conversation with your prescriber. Every date and indication below was checked against FDA records or the current FDA-approved label.

What counts as "new"

A medication can be new in different ways, and the difference matters:

• New mechanism: it works on a brain system that earlier drugs for that condition did not target. This is the kind of change that may help people who did not respond to older options.
• New molecule, familiar mechanism: a new chemical that acts much like existing drugs. It may differ in side effects or dosing, but it is not a new approach.
• New combination or new use: existing drugs combined, or an older medication approved for a new condition.

Marketing tends to blur these categories. Asking "what does this do that my current medication does not?" is the most useful question you can bring to an appointment.

Depression: Auvelity, Zurzuvae and Exxua

Auvelity (dextromethorphan-bupropion), approved August 2022

Auvelity combines dextromethorphan, which blocks NMDA receptors in the brain's glutamate system and acts on sigma-1 receptors, with bupropion, a familiar antidepressant that also slows the breakdown of dextromethorphan so it stays active longer. It is approved for major depressive disorder in adults, and in April 2026 its label added agitation associated with Alzheimer's dementia. The glutamate approach is the new element. Because it contains bupropion, it carries the same seizure precautions, including for people with eating disorders or who are suddenly stopping alcohol or sedatives.

Zurzuvae (zuranolone), approved August 2023

The FDA approved Zurzuvae as the first oral medication for postpartum depression in adults; before that, the only approved treatment specific to postpartum depression was an IV infusion given in a health care facility. It is a neuroactive steroid that modulates GABA-A receptors and is taken as a 14-day course rather than daily for months. It has a boxed warning about driving impairment: people should not drive or do other hazardous activities for at least 12 hours after each dose. It is a Schedule IV controlled substance, and alcohol adds to its sedating effects. See our page on postpartum depression treatment.

Exxua (gepirone), approved September 2023

Exxua is approved for major depressive disorder in adults and works mainly by stimulating serotonin 5-HT1A receptors, rather than blocking serotonin reuptake as SSRIs do. Its label requires an ECG before starting and during treatment because of effects on heart rhythm (QT interval). It is a newer approach to serotonin, though not to a new neurotransmitter system.

Schizophrenia and bipolar disorder: Cobenfy and Bysanti

Cobenfy (xanomeline and trospium chloride), approved September 2024

The FDA described Cobenfy as the first antipsychotic approved for schizophrenia that targets cholinergic receptors instead of dopamine receptors, which every previous antipsychotic had relied on. Xanomeline stimulates M1 and M4 muscarinic receptors in the brain; trospium blocks muscarinic receptors in the body to reduce side effects such as nausea. It is approved for schizophrenia in adults. Its label warns about urinary retention, faster heart rate, slowed stomach emptying and swelling of the face and lips, and requires liver tests before and during treatment.

What is still unknown: its approval rested on two five-week trials, so long-term experience is limited compared with antipsychotics used for decades, and there is little head-to-head data against those older drugs. Its side-effect profile differs from dopamine-blocking drugs, which may matter for people troubled by weight or movement side effects, but how it compares over years is not yet known.

Bysanti (milsaperidone), approved February 2026

Bysanti is approved for schizophrenia and for acute manic or mixed episodes of bipolar I disorder in adults. It is a good example of a new molecule with a familiar mechanism: its label explains that milsaperidone and iloperidone, an older antipsychotic, rapidly convert into each other in the body, and that it works through dopamine and serotonin blockade like other atypical antipsychotics. For more on how these medications are chosen, see integrative bipolar medication management.

ADHD: Simtriyo (centanafadine), approved July 2026

The FDA approved Simtriyo on 24 July 2026 for ADHD in adults and children aged 6 and older who weigh at least 20 kilograms. Its maker describes it as the first approved norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD, adding serotonin to the two neurotransmitters that existing stimulants mainly affect. It is classified as a central nervous system stimulant and carries boxed warnings for suicidal thoughts and behaviors in children and for abuse, misuse and addiction.

As of September 2026 the manufacturer reported it was still under DEA scheduling review, and we found no scheduling rule published in the Federal Register as of October 2026, so it is not yet available to prescribe. How it will compare with established ADHD medications in everyday use is not known. Our guide to stimulant and non-stimulant ADHD medication covers the current options, and ADHD medication by telehealth explains the rules for controlled medications.

A quick comparison

Approval dates and indications come from the FDA and from each medication's current label. Approval is the start of a medication's story, not the end: labels are updated as new uses are approved and new safety information arrives, as Auvelity's 2026 update shows.

Why "new" does not mean "better for you"

A new mechanism is promising, especially for people who have tried several older medications without success. But a new approval also comes with real unknowns:

• Shorter track records. Pivotal trials often last weeks. Rare side effects and long-term effects usually surface only after many thousands of people have used a drug for years.
• Few head-to-head comparisons. Most approvals compare the new drug with a placebo, not with the medications you might already be taking.
• Cost and coverage. Newer brand-name drugs are often expensive, and plans may require trying older options first.
• Interactions and monitoring. Some need ECGs, liver tests or special timing, as described above.

Older medications have decades of data on what happens in pregnancy, in older adults, and over long periods. For many people a well-chosen, carefully dosed older medication remains the better option. For others, especially after several unsuccessful trials, a new mechanism may be worth discussing. Our pages on treatment-resistant depression and precision psychopharmacology cover how those decisions are approached.

Talking to your prescriber about a newer medication

If you read about a new medication and wonder whether it could help you, bring it up. Useful questions:

1. What does this medication do differently from what I have already tried?
2. What did the trials show, and how long did they last?
3. What would we monitor, and how often?
4. What would it replace, and how would we switch safely?
5. What would it cost me, and is there an established option that fits just as well?

A thoughtful prescriber will discuss newer options honestly, including when they are not the right fit. At Willow & Stone, any medication decision is made together and weighed against your history, your other medications and the rest of your medication management plan. Mentioning a medication here does not mean it is right for you or that it is part of any particular treatment plan.

Common Questions

Sources & Further Reading

• FDA — Novel Drug Approvals for 2026
• FDA — FDA approves drug with new mechanism of action for treatment of schizophrenia (Cobenfy, 26 Sep 2024)
• FDA — FDA approves first oral treatment for postpartum depression (Zurzuvae, 4 Aug 2023)
• DailyMed — Auvelity (dextromethorphan-bupropion) prescribing information
• DailyMed — Bysanti (milsaperidone) prescribing information
• DailyMed — Exxua (gepirone) prescribing information
• Otsuka — Simtriyo (centanafadine) Phase 3b results and approval status (18 Sep 2026)

This article is general education, not advice for your situation. Do not start, stop, or change a medication or supplement without talking to the clinician who prescribes it.